Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iGlarLixi in Type 2 Diabetes
NCT06716424Phase 4Completed
- Sponsor
- Sanofi
- Start
- Jan 2025
- Primary completion
- Jun 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of insulin glargine + lixisenatide in type 2 diabetes mellitus (T2DM), sponsored by Sanofi. Primary endpoint: Percentage of participants with treatment emergent adverse events (TEAEs) including serious adverse events (SAEs) at 25 weeks. Started Jan 2025; status: completed.
02
Drugs
insulin glargine + lixisenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06716424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06716424.